Tiziana Life Sciences (NASDAQ:TLSA) is a biotechnology firm dedicated to discovering and developing novel therapies that can potentially transform the treatment of diseases in fields such as immunology and oncology. At the heart of its operations are projects targeting the modulation of the human immune system, aiming at diseases that currently have limited treatment options. Their objectives include advancing their pipeline of therapeutic candidates through clinical trials with the ultimate goal of bringing transformative treatments to market. The company's research focuses on leveraging its expertise in monoclonal antibodies and small molecules to potentially improve patient outcomes in areas such as multiple sclerosis, Crohn's disease, and cancer.